Company Overview and News

Analyst Reports

NEW capital market measures, a stronger ringgit, a stronger pipeline of initial public offerings (IPOs) and the upcoming general election are some of the key catalysts for Bursa Malaysia Bhd.

EITA wins RM126m in jobs from Prasarana

2018-03-07 themalaymailonline
In a filing with Bursa Malaysia (pic), EITA Resources says it has secured contracts worth RM126 million from Prasarana. — Picture by Azneal IshakPETALING JAYA, March 7 — Elevator maker EITA Resources Bhd has secured three letters of acceptance from Prasarana Malaysia Bhd with value of RM126.19 million, according to The Star.

Eita shares up 4.8% on contract win

KUALA LUMPUR: Shares of Eita Resources Bhd rose 4.85% in morning trades supported by the company securing contracts worth RM126.19mil.

Trading ideas: Eita Resources, MMC, Leweko

KUALA LUMPUR: JF Apex Research expect Eita Resources Bhd , MMC Corp Bhd and Leweko Resources Bhd to attract trading interest today following their latest corporate news.

EITA gets RM126mil jobs from Prasarana

PETALING JAYA: Elevator manufacturer EITA Resources Bhd has clinched three letters of acceptance from Prasarana Malaysia Bhd worth RM126.19mil.

Trading ideas: Mudajaya, EITA Resources, Hap Seng, 7-Eleven

KUALA LUMPUR: JF Apex Research expects Mudajaya Group Bhd , EITA Resources Bhd , Hap Seng Consolidated Bhd , 7-Eleven Malaysia Holdings Bhd and Datasonic Group Bhd to be among the stocks to watch on Thursday.

Trading ideas: Scientex,Vsolar, WTK, IOI Corp, Ann Joo

KUALA LUMPUR: Scientex Bhd , Vsolar Group Bhd , WTK Holdings Bhd , Ann Joo Resources Bhd and IOI Corp Bhd are among the stocks to watch on Monday, according to JF Apex Research.

Trading ideas: Hartalega, F&N, Talam, Sunway REIT, Eita, Pasukhas

KUALA LUMPUR: Hartalega Holdings Bhd , Fraser and Neave Holdings Bhd (F&N), Talam Transform Bhd , Sunway REIT, Eita Resources Bhd and Pasukhas Group Bhd are among the stocks to watch, according to JF Apex Research.

CIMB Research retains Add for Eita, target price of RM2.40

KUALA LUMPUR: CIMB Equities Research is retaining its Add recommendation for Eita Resources Bhd and target price of RM2.40, which is 34.8% above the last traded price of RM1.78. It on Tuesday maintained its EPS forecasts and target price, based on 12 times FY18F P/E (20% discount to its target 15 times P/E for the construction sector).  “The discount is to reflect its small market cap and indirect exposure to the sector.

Xinghe, Anzo, CAB, EITA, EUPE, Freight Management, HSS, Public Packages, Rev Asia

2017-03-24 theedgemarkets
KUALA LUMPUR (March 24): highlighted 13 stocks with momentum at Bursa Malaysia’s afternoon market close today. It showed one with positive momentum and twelve with negative momentum.

KLCI falls 0.37% in line with regional back pedal

2016-11-24 theedgemarkets
KUALA LUMPUR (Nov 24): The FBM KLCI fell 0.37% at the midday break today, as regional markets back-pedalled.

Eita Resources, Astro, Willowglen, EKA Noodles, Maypak, LBS Bina and Melewar

2016-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (Sept 15) could include: Eita Resources, Astro, Willowglen, EKA Noodles, Maypak, LBS Bina and Melewar.

KLCI falls 8pts on Sime Darby, profit taking

2016-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): The FBM KLCI fell eight points or 0.5% on Sime Darby Bhd share losses and as investors took profit after the index's recent gains.

KLCI pares loss, tepid mood prevails

2016-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): The FBM KLCI pared some of its losses at mid-morning today but the prevailing tepid sentiment kept the index in the negative zone.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...